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1. Introduction
  There is evidence that host genetic factors are important 
determinants of mycobacterial susceptibility. Different 
techniques have been employed to identify the genes 
implicated[1]. Some genes that codify for different cytokines 
may play crucial roles in host susceptibility to tuberculosis 
(TB), because the production capacity of these cytokines 
varies among individuals and depends on the single 
nucleotide polymorphisms (SNPs) of these[2]. Recently we 
reported that TB patients not responding to treatment, 
occurred more frequently genotype LTA +252G/A[3]. 
Interleukin-10 (IL-10) converts human dendritic cells into 
macrophage-like cells with increased antimycobacterial 
activity[4]. IL-10 is an important immunoregulatory cytokine 
mainly produced by activated T cells, monocytes, B cells 
and thymocytes. As an immune response modulator, IL-10 
can both stimulate and suppress the immune response[5]. 
There are three bi-allelic polymorphisms genetically 
regulating in vivo production of IL-10 in promoter gene. 
In the -1082 position of the transcription initiation site, 
the polymorphism constitutes a substitution by G of A, 
and in the -592 position, is the substitution by C of A. The 
presence of G and C is associated with greater production 
of IL-10, and A with less in Peripheral blood mononuclear 
cell (PBMC) cultures[6]. The low-expression IL-10 -1082 
AA genotype is found increased in patients with cutaneous 
malignant melanoma[7].
  The IL-10 -1082 G allele can be relevant for susceptibility 
to celiac disease, mainly in selective IgA deficiency[8]. 
The G allele of the -1082 single nucleotide polymorphism 
(SNP) is associated with low liberation of IL-10 after 
cardiopulmonary bypass. High levels of IL-10 secretion 
are related with organ dysfunction 24 h post-surgery[9]. 
The -1082 SNP G濚A SNP exerted an influence on the 
achievement of longevity in males[10]. The A allele of 
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the -592 SNP was associated with less stimulation of 
IL-10 liberation and increased liberation in critically 
ill patients[11]. The IL-10 genotype was related with 
the frequency of Respiratory syncytial virus (RSV)-
associated pneumonia[12]. An increased frequency has been 
demonstrated of the -1082 GG genotype (implicated in high 
production of IL-10) in patients recovered from hepatitis 
C virus (HCV) infection[13]. Patients homozygous for the G 
allele of the -1082 SNP had a greater risk for septic shock[14]. 
This was associated more frequently with the GG genotype of 
the -1082 SNP, and with increased severity of the systemic 
inflammatory response syndrome (SIRS) associated with 
Community-acquired pneumonia (CAP)[15]. 
  The IL-10 gene also can be implicated in genetic 
susceptibility to TB. It has been suggested that -1082 IL-10 
AA low-producer polymorphism is associated with pleural 
TB[16]. The heterozygous for the -1082 polymorphism has 
been associated with susceptibility to TB in Camboyan 
patients[17]. A reduction in the -1082 A allele is related with 
long-lived Sicilian individuals with chronic TB[18]. It has 
also been demonstrated that the frequency of the -1082 G 
allele was more common in Turkish patients with TB than in 
healthy controls[2].
  In Uganda, some authors reported that the IL-10 gene is 
associated with TB[19]. A direct inter-relationship was shown 
between IL-10 and the severity of both pulmonary as well 
as extra-pulmonary TB[20]. The -1082 A allele of the IL-10 
gene can be important in susceptibility to TB[21]. IL-10 is 
important for effective control of inflammation in the host 
with TB[22].
  On the other hand, there is an alarming prevalence of T2D 
in Mexican population; the majority of previously diagnosed 
are in poor control. The prevalence for T2D was 14.42%; 
(7.3 million diabetics)[23]. Because type 2 diabetes (T2D) is 
very prevalent among cases of TB in Mexico, the objective 
of this work was to determine the IL-10 polymorphisms in 
pulmonary TB (PTB) that are complicated by T2D and in TB. 
We carried out a study in Mexican mestizo population, PTB 
complicated by T2D (TB + T2D), cured TB, non-cured TB, 
Blood bank donors, and in positive tuberculin (PPD+) health 
workers. The real contribution of IL-10 polymorphisms 
in terms of the risk for TB is unknown. To our knowledge, 
there are no studies that have investigated the contribution 
of these T2D-complicated TB. Thus, this study is of the 
greatest importance. 
2. Materials and methods
  In a study conducted 2 years ago, we collected by simple 
random sampling, peripheral blood samples from 37 adult 
patients with TB in remission (TBr), from 40 patients with 
active pulmonary TB (PTB), from 21 patients with T2D-
complicated TB, from 47 Blood Bank donors, and from 13 
healthy, tuberculin skin test positive (TST+) health-care 
workers. We excluded from the study individuals with an 
acute or chronic infection different from TB, those infected 
with Human immunodeficiency virus (HIV) and/or hepatitis 
B or C, and those having autoimmune diseases or any other 
immune suppression-associate condition. Patients were 
treated with a regime recommended by the World Health 
Organization (WHO). 
Criteria for the screening of TBr:
1. We considered patients with TBr as those who presented 
an adequate microbiological and clinical response to the 
first treatment scheme.
Criteria for the screening of PTB:
1. Signs and symptoms compatible with TB. History of 
interpersonal contact with a case of smear-positive 
pulmonary tuberculosis. 
2. Isolation of the bacillus in sputum. 
3. Abnormal chest radiograph, showing mediastinal 
lymphadenopathy and/or hilar or other lesions consistent 
with TB. 
Criteria for the screening of T2D:
1. A casual blood glucose greater than or equal to 200 mg/dL 
(11.1 mmol/L). 
2. Fasting plasma glucose equal to or greater than 126 mg/dL 
(7 mmol/L). 
3. Plasma glucose at 2 h longer or equal to 200 mg/dL (11.1 
mmol/L) during the test, oral glucose tolerance. 
4. All patients had adequate metabolic control.
  We also studied a sample of unrelated blood donors and of 
health-care personnel with TST+ who were asymptomatic 
and with a chest X-ray without evidence of pulmonary 
disease. All participants were of Mexican mestizo origin and 
were followed-up for 18 months to confirm their diagnosis 
or control. The study was approved by the local Ethics 
Committee, and all participants provided written informed 
consent. 
2.1. Subjects genotyping 
  Genomic DNA was extracted with guanidine isothiocyanate 
and phenol according to the procedure described by 
Chomczynski[24]. IL-10 gene (-592 C/A and -1082 G/A) 
polymorphisms were typified utilizing ABI PRISM 7300 
(Applied Biosystems) Polymerase chain reaction (PCR). We 
use accessory software to analyze the distribution of each 
pair of alleles. The TaqMan allelic discrimination assay 
used 5’ nuclease activity of the Taq polymerase to detect a 
reporter signal generated during or after the PCR reactions. 
For SNP genotyping, we employed a pair of TaqMan probes 
and a pair of primers. The assays utilize two TaqMan probes 
that differ in the polymorphic site, with a complementary 
probe to the wild-type allele and the remaining probe, 
to the variant allele. A 5’ reporter colorant and a 3’ color 
quencher bind covalently with the probes with the allele 
or with variant. When the probes are intact, fluorescence 
is quenched by the physical proximity of the reporter 
and quencher colorants. During the PCR alignment step, 
the TaqMan probe hybridize with the target polymorphic 
target site. During the PCR extension phase, the 5’ reporter 
colorant breaks due to the 5’ nuclease activity of the Taq 
polymerase and leads to an increase in fluorescence, which 
is characteristic of the reporter colorant. Specific genotyping 
determined by measuring the signal intensity of the two 
different reporter colorants after the PCR reaction. The 
volume of the reaction was 25 毺L, containing 2×TaqMan 
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Buffer A, 3.5 mmol/L MgCl2, 200 毺mol dATP, dCTP, and 
dGTP, respectively, 400 毺mol dUTP, 0.025 U/毺L Ampli 
Taq Gold DNA, 900 nmol of forward and reverse primers, 
250 nmol/L of each Minor groove binder (MGB) TaqMan 
probe, and from 1 to 20 ng of DNA substrate. We employed 
TaqMan MGB probes (assay number C__1747360_10), which 
detects the (-592 C/A SNP) localized in the rs1800896 region, 
and assay number (C__1747363_10), which detects the (SNP 
-1082 G/A SNP) localized in the rs1800872 region of the IL-
10 gene. Probe sequences were the following:
  T C C T C T T A C C T A T C C C T A C T T C C C C [ A / C ]
T C C C A A A G A A G C C T T A G T A G T G T T G  a n d 
C T T T C C A G A G A C T G G C T T C C T A C A G [ A / G ]
ACAGGCGGGGTCACAGGATGTTC, respectively. Each probe 
contains one reporter colorant in the extreme 5’; the VIC® 
colorant binds with the catheter with allele 1, and the FAM 
colorant binds to the catheter with allele 2. The increase of 
fluorescence in VIC® and FAM followed in real time with 
each cycle by means of emission filters optimized for the 
use of fluorophores in the yellow channel (530 nm excitation 
and 555 nm emission), and in the green channel (470 nm 
excitation and 510 emission), respectively. The thermal 
profile was as follows: initial denaturalization, 1 cycle at 95 曟
for 10 min; 40 denaturalization cycles at 92 曟 for 15 s, and 
alignment/extension at 60 曟 for 1 min. Each sample was 
mounted and analyzed by duplicate and we included three 
negative controls without template in each run.
2.2. Statistical analysis 
  To calculate sample size, we used the overall frequency 
of alleles in healthy controls reported in previous study[11], 
the estimated difference for the different alleles of the 
polymorphisms of the IL-10 in patients with pulmonary 
TB (PTB) is approximately 25%, we use the method of 
comparison of proportions taking a confidence level of 5% 
and 80% power. 
  The study groups were examined by means of descriptive 
statistics utilizing central tendency and dispersion 
measurements as quantitative variables, while we employed 
frequency tables and/or percentages for nominal variables. 
To determine the possible associations of the variables in the 
study groups, we used contingency tables and independent 
χ2 test or statistical analysis. For continuous variables, we 
applied the Wilcoxon sum of ranges (the Mann-Whitney U 
test). Statistical significance was considered with P≤0.05. 
Odds ratio (OR) was calculated with the 95% Confidence 
interval (95% CI).
3. Results 
  The demographic data of patients with TBr and PTB, TB + 
T2D, normal control subjects, and health-care workers who 
were TST+ are represented in Table 1.
Table 1
Demographic data of the study population.
Study population Age (years)      Gender(M/F)
Healthy subjects (n=47) 34.0依6.2 31/16
Health-care workers TST+ (n=13) 31.6依5.0 8/5
Patients with PTB (n=40) 54.9依9.8 15/25
Patients with TBr (n=37)                                  44.7依6.5 15/22
Patients with TB + T2D (n=21)   55.0依10.6 9/12
F, feminine; M, masculine; PTB, Pulmonary tuberculosis; TBr, 
Tuberculosis in remission ; T2D, Type 2 diabetes ; TST+, tuberculin 
test positive.
3.1. Allele frequency IL-10
  To analyze the frequency of alleles in the studied 
population, we brought together patients with TBr and with 
PTB, and healthy blood donors with health workers who 
were TST+. The C/A allele distribution of the IL-10 -592 
Table 2
Allele frequency in the study population.
Study population -592 Allele frequency Allele A/Allele C             -1082 Allele frequency Allele A/Allele G
Healthy subjects (n=60) 0.36/0.64 0.28/0.72
Patients with TB (n=77) 0.38/0.62 0.16/0.84
Patients with TB + T2D (n=21)                 0.26/0.74 0.50/0.50
TB = Tuberculosis; T2D = Type 2 diabetes.
Table 3
Genotype distribution in the study population.
Genotype  Healthy(n=47) TST+(n=13) PTB(n=40)  TBr(n=37) TB + T2D(n=21) OR (95% CI) P value
Genotypes of IL-10 (-592 C/A)
AA (%) 0 (0) 1 (8) 1 (2) 0 (0) 1 (5)   10.8 (3.8-30.7)     <0.000 1*
CA (%) 34 (72)   8 (61) 28 (70) 29 (78)   9 (43)     0.31 (0.10-0.92) 0.05
CC (%) 13 (28  4 (31) 11 (28)   8 (22) 11 (52)     3.5 (1.2-9.9)     0.018*
Genotypes of IL-10 (-1082 G/A)
AA (%)  4 (10) 0 (0) 2 (5) 1 (3) 6 (29)     3.0 (0.67-13.4) NS
GA (%) 18 (29)   7 (54) 11 (28)  9 (22) 9 (42)     2.0 (0.62-6.9) NS
GG(%) 25 (61)   6 (46) 27(67) 27 (75) 6 (29)     6.2 (1.32-29.38)   0.04*
Values are the number (%) of subjects with each genotype. Statistical analysis of genotype frequencies was carried out by 氈
2 test with the 
continuity correction. 95% CI = 95% Confidence interval; NS = Not significant; OR = Odds ratio; PTB = Pulmonary tuberculosis; TBr = 
Tuberculosis in remission; T2D = Type 2 diabetes; TST+ = Tuberculin test positive. *Comparison between TB + T2D and healthy donor 
Guadalupe García-Elorriaga et al./Asian Pacific Journal of Tropical Medicine (2013)505-509508
polymorphism and G/A of the -1082 were similar in healthy 
subjects, with the two alleles occurring at an approximate 
ratio of 2:1 and all did not show significant differences 
(Table 2). 
3.2. Genotype frequency IL-10
  The results of genotyping of the population under study 
may be observed in Table 3. The five groups fell within 
Hardy-Weinberg equilibrium, with non-significant values 
by χ2 test for the genotype observed and expected for 
each of the polymorphisms tested[25]. The IL-10 genotype 
did not differ significantly between healthy subjects and 
cases of cured TB and non-cured TB. In contrast, the -592 
CA genotype presented in a greater proportion in healthy 
subjects than in patients with TB + T2D with statistical 
significance. Similarly, the -1082 AA genotype was found 
more frequently in patients with both diseases as compared 
with healthy individuals, also with statistical significance. 
4. Discussion
  Distribution of IL-10 gene polymorphisms appears to 
have an ethnic distribution, because its frequency varies 
depending on the population studied, in addition to its 
known association with the major histocompatibility 
complex (MHC)[11,18,25-28]. Our study has limitations, the 
healthy individuals are not a well defined group, may be TST 
positive or negative, they were much younger than patients, 
and limitations of groups sizes. 
  This study describes two important new findings. 
First, it reveals that the IL-10 (-592 A/A and -592 C/C) 
polymorphisms were found in a greater proportion in a 
group of patients with T2D and TB than in healthy subjects. 
Second, the study provides evidence that the (-1082 G/G) 
polymorphism presented with greater frequency in healthy 
individuals than in patients with both of these diseases. 
  The IL-10 (-592 C/A) allele frequency in healthy subjects 
correlated with other report, differing for the (-1082 G/A) 
allele frequency[28].With regard to TB, our findings coincide 
with those reported in African population[29], and diverging 
from what was reported in China where they find, the 
genotype frequencies of A/A of IL-10 in the PTB patient 
group were higher than that of control group[30]. With respect 
to the G/A genotype of the -1082 SNP, its frequency was 
greater in healthy subjects, although without statistical 
significance, diverging from that reported in Turkey, where 
it was found associated with a risk for TB[31].
  Regarding the G/G genotype of the -1082 SNP, this was 
found to be more frequent in Mexican healthy population 
compared with patients with both diseases, coinciding with 
that reported in Brazilian population[32], as well as with 
those reported in Egypt, whereIL-10-1082 G/G genotype did 
not exhibit significant association except for increased GG 
frequency in PTB [33-36].
  Although the protective mechanisms against clinical TB 
disease by increased IL10 are not fully understood, several 
clues were reported. Much higher serum IL10 was detected 
in patients with clinical TB suggesting that IL10 plays a 
role in susceptibility to tuberculosis[37,38,39].  The clinical 
characteristics of TB and maybe, the treatment failure are 
due to host-mycobacteria interaction, where is not well 
defined the role of the host’s genetics factors.  Although the 
high failure rate for TB therapy suggests factors like non-
compliance or drug resistance, neither we found association 
between any genotype of the IL-10 SNPs studied with an 
anti-TB treatment response.
  We think that there are many more polymorphic regulator 
genes that can potentially exert an influence and that 
although these have not yet been studied in patients with 
TB, additional studies are necessary in this regard. A larger 
sample size is needed to study the association between gene 
polymorphisms and diseases. This was low in our study, and 
using cohorts such as this can lead to false positive and/
or negative associations, which is probably the case here. 
The results must be confirmed by further studies with larger 
sample sizes. 
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